Aurigene is a contract research, development and manufacturing organization (CRDMO) offering truly integrated services in the discovery, development and commercialization of small and large molecules to global innovative pharma and biotech companies.
Beyond science, our operations are rooted in the fundamental principles of compliance, information security, quality, and sustainability. As an environmentally responsible company, we continue delivering on our ESG goals. We became water-positive in 2023 and are working on ambitious goals to reduce our carbon footprint. In numbers, we aim to switch to 100% renewable power by 2030 and achieve carbon neutrality in our direct operations (Scope 1 and Scope 2 emissions) by 2030 and a 12.5% reduction in indirect carbon emissions across our supply chain (Scope 3 emissions) by 2030.
Services
In the discovery space, Aurigene boasts a legacy of more than 25 years of operations and has long-term partnerships with two of the top five pharmaceutical companies. We offer chemistry, biology, and integrated services across the life cycle of drug discovery, from target identification to IND filing. We operate in a flexible manner and offer our services in FTE and/or FFS mode; integrated and/or standalone mode.
Chemistry
Biology
FormulationsLeading CRO/CDMO and a long-term partner
We are uniquely positioned to serve our customers and accelerate their journey to the clinic from discovery to commercialization by nurturing long-term partnerships.
Read more about our infrastructure to see how we are positioned to provide end-to-end services:
Read More
Why Aurigene Pharmaceutical Services?
20+
years’ experience
900+
scientists
125+
global clients
600+
projects
19
NCEscommercialized
16
USFDA inspectedcGMP facilities
6
Biologicscommercialized
3
manufacturing countriesUK, Mexico, India
Virtual Tour
Hyderabad R&D Center
Bangalore R&D Center
Client Speak
I’m very satisfied with the chemistry work at APSL, collaborated both chemistry (FTE) and biology (FFS). Technical discussion, weekly updates and meetings were good.
Testimonial By Biotech, US
APSL is very flexible in allocating FTEs and shipping compounds to the preferred destination. Updates on raw material, reports and LNBs are remarkable. Quick turn around time for solving problems using analytical techniques.
Testimonial By Large Pharma
Based on the FFS experience with APSL, it increased the bandwidth from FFS to FTE business. The level of communication and transparency in communication was excellent. Project reports and weekly updates are prepared well and on time.
Testimonial By CMC Director, Large Pharma
Based on the pilot peptide program, we extended an FTE collaboration with Aurigene. The scientific team was excellent in communication and problem-solving. The management was proactive and ready to invest in capability and capacity building.
Testimonial By Large pharma, US
Happy with the quality of product, productivity and problem-solving capacity. Proactive communication about shipments helped us to plan our studies efficiently. APSL is a one-stop-shop for our discovery and development needs.
Testimonial By Large pharma, EU
Happy with the scientific team, hence restarted research collaboration. The team is very responsible, trustable, and reliable. All discovery services are under one roof.
Testimonial By Biotech, USConnect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
FEBRUARY 25, 2025
Transforming Drug Discovery with Aurigene.AI
In the early 2000s, developing Sovaldi, a hepatitis C treatment, took over a decade and nearly $2 billion. Similarly, Zolgensma, a gene therapy for spinal muscular atrophy, required 15 years due to its complexity. However, the advent of artificial intelligence (AI) has revolutionized drug discovery. For example, in 2022, Pfizer's PAXLOVID, an oral COVID...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Familiarization, process optimization, and cGMP manufacturing and supply of 30.0 kg of a Bioactive Nucleotide (NAD Booster)
Background: A US-based biopharmaceutical company approached Aurigene Pharmaceutical Services for the familiarization, process development, and cGMP manufacturing and supply of 30.0 kg Nucleotide product (NAD booster) for phase-appropriate studies. The synthesis of the desired product involves three linear stages, which starts with reaction of a pentose...
Read More
Identification of Degradants of Thermal and Oxidation Stress Studies of Empagliflozin and Linagliptin Tablets by HPLC-PDA and LC-MS Instrumental Techniques
2022
Objective of the manuscript is to identify the degradants observed in the thermal and oxidation degradation sample of Empagliflozin and Linagliptin tablets by using LC-MS and HPLC-PDA instrumental techniques. Thermal and oxidation degradation samples were injected in HPLC-PDA and LC-MS instruments. Mass of the degradants were detected by LC-MS technique, ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market